Stay updated on Phase II Anti-PD1 Epigenetic Therapy Clinical Trial
Sign up to get notified when there's something new on the Phase II Anti-PD1 Epigenetic Therapy Clinical Trial page.

Latest updates to the Phase II Anti-PD1 Epigenetic Therapy Clinical Trial page
- CheckyesterdayChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, as well as new content related to various biochemical compounds and proteins. Notably, azacitidine and entinostat have been removed, indicating a shift in focus or product offerings.SummaryDifference3%
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%
- Check22 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11, indicating a revision in the content.SummaryDifference0.1%
- Check29 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.9%
- Check36 days agoChange DetectedThe web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.SummaryDifference0.2%
- Check44 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.1%
Stay in the know with updates to Phase II Anti-PD1 Epigenetic Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase II Anti-PD1 Epigenetic Therapy Clinical Trial page.